Furthermore, studies assessing HE4 and CA125 as a combined indicator of prognosis have shown positive results, with a sensitivity of 76.4% and specificity of 95%.[14] Although HE4 is already well established as a biomarker for monitoring EOC patients, its potential use in other types of cancer such as endometrial and lung cancer, as well its use as a prognostic and diagnostic marker is still being investigated. Here, WFDC2 is linked to cancer.